Dr Marie Ann RoskrowChairperson
Dr Roskrow gained a BSc(Hons), MBBS (Hons) degree and a PhD in Immunology from the University of London. She has more than 25 years of experience as a physician / medical researcher, investment banker, CEO and chairperson in both private and listed companies such as the GSF Research Institute (Munich), Patrys Ltd (Melbourne), Imevax (Munich) and Lazard Healthcare Investment Banker (New York, San Francisco, Sydney). During her 8 years at Lazard, Marie executed a wide-range of complex strategic transactions including: mergers and acquisitions, joint ventures and asset divestitures. Additionally she was involved in the execution of > 50 financing deals including: IPOs, capital raisings and structured debt. Marie holds 0 shares in Biotec Pharmacon
Mr. Wedershoven has a MBA from Ludvig Maximillian University, Munchen, Germany and has a wide background within entrepreneurship, finance and strategy. Mr. Wedershoven has more than 30 years of industrial experience and was amongst others responsible for development of Seidenader Machinenbau, a global supplier of production equipment to the pharmaceutical industry. He sold the company in 2010 with close to 500 employees to a large equipment supplier in Germany. Mr. Wedershoven holds several board and management positions in smaller German companies. Volker holds 0 shares in Biotec Pharmacon
Ms. Rydin holds a Master of Science degree from Chalmers University of Technology, Sweden. Ms. Rydin was elected to the Board in 2014. Her latest assignments have been as CEO of entrepreneurial companies in the Life Science and Health Care industry. Before this she was serving as VP Wound & Skin Care Global Marketing of Coloplast and Managing Director of the Mölnlycke Health Care subsidiary in Eastern Europe. Ms. Rydin started her career in SCA Hygiene / Mölnlycke in 1981 in Research & Development and has held a range of management positions in Marketing & Sales. Rydin holds no shares in Biotec Pharmacon.
Mr. Reinemo has an MBA from the University of Chicago and has more than 25 years of experience within consultancy and investments from companies such as McKinsey, Kistefos, Creo Partners and Siljan Industrier. Arne has extensive board experience through several board positions, including chairman of Nextgentel and TopTemp Holding. Arne holds 0 shares in Biotec Pharmacon
Ms. Skjæveland holds a Civil Engineer in Biotechnology and a PhD in Immunology from the University of Tromsø. Skjæveland worked as post.doc and a researcher at the University of Tromsø before she joined Biotec BetaGlucan in 2013 as a Scientific Product manager for Woulgan. She was elected as employee representative to the Board in May 2017. Number of shares in Biotec Pharmacon held by Ms. Skjæveland: 16,087. Number of options: 10,000.
Marit Sjo LorentzenEmployee Observer
Mrs. Lorentzen has a Civil engineering degree in Biotechnology and a Dr. Scient in Molecular Biology degree from the University of Tromsø. Marit worked at the University of Tromsø until 2011. She has extensive work experience within laboratory operations, management and research. This also includes experience within teaching, field of studies in biochemistry, molecular biology, microbiology, fermentation and purification. She holds a position as Production Manager in ArcticZymes. Number of shares in Biotec Pharmacon held by Mrs. Lorentzen: 20,331 Number of options: 0